S. Gail Eckhardt

7.3k total citations · 2 hit papers
105 papers, 5.3k citations indexed

About

S. Gail Eckhardt is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, S. Gail Eckhardt has authored 105 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Oncology, 47 papers in Molecular Biology and 25 papers in Cancer Research. Recurrent topics in S. Gail Eckhardt's work include Colorectal Cancer Treatments and Studies (21 papers), Cancer Treatment and Pharmacology (15 papers) and Cancer Genomics and Diagnostics (14 papers). S. Gail Eckhardt is often cited by papers focused on Colorectal Cancer Treatments and Studies (21 papers), Cancer Treatment and Pharmacology (15 papers) and Cancer Genomics and Diagnostics (14 papers). S. Gail Eckhardt collaborates with scholars based in United States, France and Italy. S. Gail Eckhardt's co-authors include Laura Q.M. Chow, Manuel Hidalgo, Pamela M. Holland, Avi Ashkenazi, Todd M. Pitts, Wells A. Messersmith, John J. Tentler, Natalie J. Serkova, Lia Gore and David R. Milich and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

S. Gail Eckhardt

105 papers receiving 5.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sunitinib: From Rational Design to Clinical Efficacy

2007 718 citations S. Gail Eckhardt et al. Journal of Clinical Oncology profile →
Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy

2001 655 citations S. Gail Eckhardt et al. profile →

Peers

Countries citing papers authored by S. Gail Eckhardt

Since Specialization

Citations

This map shows the geographic impact of S. Gail Eckhardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Gail Eckhardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Gail Eckhardt more than expected).

Fields of papers citing papers by S. Gail Eckhardt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Gail Eckhardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Gail Eckhardt. The network helps show where S. Gail Eckhardt may publish in the future.

Co-authorship network of co-authors of S. Gail Eckhardt

This figure shows the co-authorship network connecting the top 25 collaborators of S. Gail Eckhardt. A scholar is included among the top collaborators of S. Gail Eckhardt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Gail Eckhardt. S. Gail Eckhardt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer 2024 ·Clinical Cancer Research ·Robert W. Lentz, (unknown), Patrick J. Blatchford, Kimberly R. Jordan, Todd M. Pitts, Hannah R. Robinson, S. Lindsey Davis, (unknown), Alexis D. Leal, (unknown), (unknown), (unknown), (unknown), Stacey M. Bagby, Sarah J. Hartman, S. Gail Eckhardt, Wells A. Messersmith, Christopher H. Lieu	4
2	Covalent JNK Inhibitor, JNK-IN-8, Suppresses Tumor Growth in Triple-Negative Breast Cancer by Activating TFEB- and TFE3-Mediated Lysosome Biogenesis and Autophagy 2022 ·Molecular Cancer Therapeutics ·Milad Soleimani, (unknown), Tamer S. Kaoud, (unknown), (unknown), Dennis Wylie, (unknown), Agnieszka Looney, Uma Giri, Todd Triplett, Kevin N. Dalby, Jeanne Kowalski, S. Gail Eckhardt, (unknown)	14
3	e-MutPath: computational modeling reveals the functional landscape of genetic mutations rewiring interactome networks 2020 ·Nucleic Acids Research ·(unknown), (unknown), (unknown), (unknown), Zhe Su, Daniel J. McGrail, Yang Li, Erxi Wu, S. Gail Eckhardt, Nidhi Sahni, S. Stephen Yi	12
4	Integrated Genomic Characterization of the Human Immunome in Cancer 2020 ·Cancer Research ·(unknown), (unknown), Daniel J. McGrail, Ming Sun, Dan Qi, Sachet A. Shukla, Erxi Wu, Anna Capasso, Shiaw‐Yih Lin, Catherine J. Wu, S. Gail Eckhardt, Gordon B. Mills, Bo Li, Nidhi Sahni, S. Stephen Yi	10
5	Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center 2020 ·Cancer Medicine ·Jennifer Weiss, (unknown), (unknown), Dexiang Gao, Christine M. Fisher, Anthony Elias, Virginia F. Borges, Peter Kabos, S. Lindsey Davis, Stephen Leong, S. Gail Eckhardt, Jennifer R. Diamond	1
6	RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer 2020 ·BMC Cancer ·John J. Tentler, Julie Lang, Anna Capasso, Deog Joong Kim, Ely Benaim, Young Bok Lee, Andrew Eisen, Stacey M. Bagby, Sarah J. Hartman, Betelehem W. Yacob, (unknown), Todd M. Pitts, Roberta Pelanda, S. Gail Eckhardt, Jennifer R. Diamond	21
7	Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer 2019 ·Clinical Cancer Research ·Christopher H. Lieu, Erica A. Golemis, Ilya G. Serebriiskii, Justin Y. Newberg, Amanda Hemmerich, Caitlin Connelly, Wells A. Messersmith, Cathy Eng, S. Gail Eckhardt, Garrett M. Frampton, Matthew Cooke, Joshua E. Meyer	135
8	First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer 2019 ·Molecular Cancer Therapeutics ·Anna Capasso, Stacey M. Bagby, (unknown), Naomi Currimjee, Betelehem W. Yacob, (unknown), (unknown), Deog Joong Kim, (unknown), Young Bok Lee, Ely Benaim, (unknown), Sarah J. Hartman, Aik Choon Tan, Jihye Kim, Todd M. Pitts, S. Gail Eckhardt, John J. Tentler, Jennifer R. Diamond	27
9	Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts 2019 ·Journal for ImmunoTherapy of Cancer ·Anna Capasso, Julie Lang, Todd M. Pitts, Kimberly R. Jordan, Christopher H. Lieu, S. Lindsey Davis, Jennifer R. Diamond, Scott Kopetz, (unknown), (unknown), Brian M. Freed, Betelehem W. Yacob, Stacey M. Bagby, Wells A. Messersmith, Jill E. Slansky, Roberta Pelanda, S. Gail Eckhardt	127
10	Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms 2018 ·Molecular Cancer Therapeutics ·Aaron J. Scott, John J. Arcaroli, Stacey M. Bagby, (unknown), (unknown), Natalie J. Serkova, Anna Nguyen, Jihye Kim, Andrew Thorburn, Jon D. Vogel, Kevin S. Quackenbush, Anna Capasso, (unknown), Patrick J. Blatchford, (unknown), Todd M. Pitts, S. Gail Eckhardt, Wells A. Messersmith	36
11	p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer 2015 ·Molecular Cancer Therapeutics ·John J. Tentler, (unknown), Aik Choon Tan, (unknown), Todd M. Pitts, Magdalena J. Glogowska, Peter Kabos, Carol A. Sartorius, Kelly D. Sullivan, Joaquı́n M. Espinosa, S. Gail Eckhardt, Jennifer R. Diamond	39
12	Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants 2014 ·Molecular Cancer Therapeutics ·(unknown), John J. Tentler, Aik Choon Tan, Heather M. Selby, (unknown), (unknown), S. Lindsey Davis, (unknown), Todd M. Pitts, (unknown), (unknown), Shawn M. O’Connell, Patrick W. Vincent, S. Gail Eckhardt	21
13	Common PIK3CA Mutants and a Novel 3′ UTR Mutation Are Associated with Increased Sensitivity to Saracatinib 2012 ·Clinical Cancer Research ·John J. Arcaroli, Kevin S. Quackenbush, (unknown), Todd M. Pitts, Anna Spreafico, Marileila Varella‐Garcia, Lynne Bemis, Aik Choon Tan, (unknown), Basel M. Touban, Arvind Dasari, S. Gail Eckhardt, Wells A. Messersmith	36
14	Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models 2012 ·Clinical Cancer Research ·Jennifer R. Diamond, S. Gail Eckhardt, Aik Choon Tan, (unknown), Heather M. Selby, (unknown), (unknown), Marileila Varella‐Garcia, Todd M. Pitts, Mark R. Bray, Graham C. Fletcher, John J. Tentler	39
15	Dogs Are More Sensitive to Antagonists of Inhibitor of Apoptosis Proteins Than Rats and Humans: A Translational Toxicokinetic/Toxicodynamic Analysis 2012 ·Toxicological Sciences ·Harvey Wong, Nageshwar Budha, Kristina West, Elizabeth Blackwood, Joseph A. Ware, Ron Yu, Walter C. Darbonne, Stephen E. Gould, Ronald W. Steigerwalt, Rebecca J. Erickson, (unknown), Patricia LoRusso, S. Gail Eckhardt, Andrew J. Wagner, Iris T. Chan, Michael Mamounas, John A. Flygare, Wayne J. Fairbrother	13
16	Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor–Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors 2010 ·Clinical Cancer Research ·Michael S. Gordon, Christopher J. Sweeney, David S. Mendelson, S. Gail Eckhardt, Abraham Anderson, Darrin M. Beaupre, Daniel Branstetter, Teresa L. Burgess, Angela Coxon, Hongjie Deng, Paula Kaplan‐Lefko, Ian M. Leitch, Kelly S. Oliner, Lucy Yan, Min Zhu, Lia Gore	133
17	Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors 2010 ·Clinical Cancer Research ·Jennifer R. Diamond, Bruno R. Bastos, Ryan J. Hansen, Daniel L. Gustafson, S. Gail Eckhardt, Eunice L. Kwak, Shuchi S. Pandya, Graham C. Fletcher, Todd M. Pitts, Gillian N. Kulikowski, Mark Morrow, Jamie Arnott, Mark R. Bray, Carolyn Sidor, Wells A. Messersmith, Geoffrey I. Shapiro	57
18	Phase I, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered Ad5CMV-p53, an Adenoviral Vector Containing the Wild-Type p53 Gene, in Patients With Advanced Cancer 2006 ·Journal of Clinical Oncology ·Anthony W. Tolcher, Desirée Hao, Johann S. de Bono, A. B. Miller, Amita Patnaik, Lisa A. Hammond, Leslie Smetzer, Jill Hood, James A. Merritt, Eric K. Rowinsky, Chris H. Takimoto, (unknown), S. Gail Eckhardt	34
19	Anti‐tumor activity of the combination of cetuximab, an anti‐EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases 2006 ·Journal of Cellular Physiology ·Maria Pia Morelli, Tina Cascone, Teresa Troiani, Concetta Tuccillo, Roberto Bianco, Nicola Normanno, Marco Romano, Bianca Maria Veneziani, Gabriella Fontanini, S. Gail Eckhardt, (unknown), Giampaolo Tortora, Fortunato Ciardiello	48
20	Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors 2005 ·Annals of Oncology ·Maria Pia Morelli, Tina Cascone, Teresa Troiani, Ferdinando De Vita, Michele Orditura, Gianluca Laus, S. Gail Eckhardt, Stefano Pepe, Giampaolo Tortora, Fortunato Ciardiello	98

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact